Laura Wadsten
@LWadsten
Followers
480
Following
54K
Statuses
872
reporting on market power and antitrust w/ focus on healthcare | words in @hntrbrkmedia @Capitol_Forum @jhunewsletter | DC based Minnesotan
Washington, DC
Joined August 2015
Excited to share this story I’ve been working on for months about a unique FDA exclusivity dispute between $LQDA and $UTHR The case highlights how long, complex, and contentious it can be to get a medication to market! (Timeline in thread)
Today, the FDA heads to court to defend its unprecedented decision protecting a lung drug monopoly from Liquidia competition. We will be in the room. We also spent the past few months researching the journey $LQDA has gone on to bring its treatment for severe lung conditions to market — a saga that highlights the hardball tactics used to delay the launch of new medicines that could give patients more choices and lower prices. Based on Hunterbrook Media's reporting, Hunterbrook Capital is long Liquidia (NASDAQ: $LQDA) at the time of publication. Positions may change at any time. See full disclosures on our website. Read our preview of what's at stake:
4
5
51
RT @hntrbrkmedia: NEW on $HIMS: Semaglutide Shortage Could End Any Day, Records Show One day after Hunterbrook predicted FDA would lift t…
0
14
0
As we predicted in our reporting yesterday, the FDA has resolved the shortage of the #GLP1 tirzepatide (Mounjaro and Zepbound)!
BREAKING: On the eve of tomorrow's court filing, an obesity doctor, pharmacist, and former FDA official tell Hunterbrook the GLP-1 drug tirzepatide is widely available. "Tirzepatide is not in shortage. That's not a question. The manufacturer is pushing out inventory,” said Ricki Chase, former director of an FDA Investigations Branch. [Based on Hunterbrook Media’s reporting, Hunterbrook Media is short Hims & Hers Health (NYSE: $HIMS) at the time of publication. Positions may change at any time. See full disclosures on our website.]
0
1
6
RT @SammyKoppelman: A really amazing piece on how hard it can be to bring a drug to market that helps people — from @LWadsten, who spent mo…
0
3
0
RT @SammyKoppelman: $SYM announced it is delaying the filing of its 10-K — and issuing a restatement of the restatement of its earnings — w…
0
3
0
Antitrust in academia? 👀 Interesting class action filed against the big scientific publishers. Always wondered how they got away with not paying for peer review…
0
0
2
And the biggest flex in this pic wasn’t my bicep, it was making sure my records on the wall made it into frame…
0
0
1
RT @jen_rice_: if taylor swift doesnt start dating a journalist soon this entire industry is going to collapse
0
738
0
RT @jason_kint: important moment here. What you have is a longtime Senator asking about surveillance capitalism business model similar to f…
0
53
0
RT @jason_kint: After CEO Mark Zuckerberg stands and faces survivors and victims families to apologize to them, Sen Hawley then presses CEO…
0
86
0
RT @Capitol_Forum: Health Care AT Wkly: FTC Takes Aim at NC Hospital Merger; Advocates Criticize Senate White Paper for Not Targeting GPO F…
0
1
0
RT @Capitol_Forum: Klobuchar Presses Drugmakers to De-list FTC-Disputed Patents; FTC Responds to Motions to Dismiss in Case Against U.S. An…
0
1
0
@FTC and Congress are continuing to put the heat on #pharma for how patent practices drive “outrageously high prices” in the U.S.
Health Care AT Weekly: FTC 'Discussing Next Steps' for Pharma Companies that Ignored Orange Book Warning Letters; Senate HELP Committee Investigation Complements FTC Efforts on Inhaler Market $ABBV $AZN $CVS $GSK $LLY $MPLN $MYL $TEVA $UNH h/t @AliceTrace67285 & @LWadsten
1
0
3